RGD peptides are used in biomaterials science for surface modifications with a view to elicit selective cellular responses. Our objective is to replace peptides by small peptidomimetics acting similarly. We designed novel molecules targeting alpha(v)beta(3) integrin and featuring spacer-arms (for surface grafting), which do not disturb the biological activity, from (L) N-(3-(trifluoromethyl)benzenesulfonyl) tyrosine used as scaffold. Various Arg-mimics were fixed on the phenol function, and the ortho position was used for the Coupling of OEG spacers. All peptidomimetics were active in the nM range in a binding test toward human alpha(v)beta(3) integrin (IC50 = 0.1 to 1.7 nM) and selective versus platelet integrin alpha(IIb)beta(3) Selected compounds revealed excellent ability to inhibit bone cells adhesion on vitronectin. Modeling and docking studies were performed for comparing the most active RGD peptidomimetic to cilengitide, i.e., cyclo-[RGDfN(Me)V]-. Lastly, the adhesion of endothelial cells on a cultivation support grafted with RGD peptidomimetics was significantly improved.
[EN] DNA-PK INHIBITING COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'ADN-PK
申请人:PROVINCIAL HEALTH SERVICES AUTHORITY
公开号:WO2021050059A1
公开(公告)日:2021-03-18
The present disclosure relates to DNA-PK inhibiting compounds and prodrugs thereof that are useful in the treatment of diseases, including cancer. In particular, the compounds sensitise cancers to therapies such as chemotherapy and radiotherapy.
SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
申请人:GAETA Federico C.A.
公开号:US20110039873A1
公开(公告)日:2011-02-17
The substituted pyrazolo[1,5-a]pyridine compounds in accordance with Formula 1 are strong inhibitors of phosphodiesterase and c-Jun N-terminal kinase activity.
Accordingly, Formula 1 compounds are candidate therapeutics for treating disease states such as cancer, neuropathic pain, inflammation as well as cognitive disorders such as Parkinson's Disease.
LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT
申请人:Chi Mei Corporation
公开号:US20170152443A1
公开(公告)日:2017-06-01
A liquid crystal alignment agent allowing formation of an LCD element having good reliability and less residual image, a liquid crystal alignment film, and an LCD element having the liquid crystal alignment film are shown. The liquid crystal alignment agent includes a polymer (A), a photosensitive polysiloxane (B), and a solvent (C). The polymer (A) is obtained by reacting a mixture that includes a tetracarboxylic dianhydride component (a-1) and a diamine component (a-2). The photosensitive polysiloxane (B) is obtained by reacting a polysiloxane (b-1) having an epoxy group with a cinnamic acid derivative (b-2) and an aromatic heterocyclic derivative (b-3) containing nitride, oxide or sulfide.
[EN] SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS À ACTIVITÉ MULTICIBLÉE
申请人:GAETA FEDERICO C A
公开号:WO2010144416A1
公开(公告)日:2010-12-16
The substituted pyrazolo[1,5-a]pyridine compounds in accordance with Formula 1 are strong inhibitors of phosphodiesterase and c-Jun N-terminal kinase activity. Accordingly, Formula 1 compounds are candidate therapeutics for treating disease states such as cancer, neuropathic pain, inflammation as well as cognitive disorders such as Parkinson's Disease.